Selvaratnam Karthiga, Nusair Msm, Mayurathan Pakkiyaretnam
Internal Medicine Department, Teaching Hospital Batticaloa, Batticaloa, LKA.
University Medical Unit, Teaching Hospital Batticaloa, Batticaloa, LKA.
Cureus. 2024 May 13;16(5):e60242. doi: 10.7759/cureus.60242. eCollection 2024 May.
Hemophagocytic lymphohistiocytosis (HLH) is a severe life-threatening hematological disorder characterized by the dysregulation of the immune system and a hyperinflammatory response. Prompt treatment is crucial to prevent fatality. Although primarily affecting infants, HLH can also occur in children and adults. It is classified as primary and secondary, with primary HLH being genetic and predominantly affecting children. Secondary HLH is triggered by infections, malignancy, metabolic disorders, and rheumatological conditions. Diagnosis is based on the HLH-2004 criteria, considering clinical and laboratory parameters. Early diagnosis and treatment improve prognosis. Treatment follows the HLH-94 and HLH-2004 protocol and consists of eight weeks of induction therapy with cyclosporine, corticosteroids, and etoposide. This case describes a 26-year-old female diagnosed with HLH and successfully treated according to the protocol. The patient exhibited improvement and was discharged, demonstrating the importance of early diagnosis and appropriate management in adult HLH cases.
噬血细胞性淋巴组织细胞增生症(HLH)是一种严重的、危及生命的血液系统疾病,其特征为免疫系统失调和过度炎症反应。及时治疗对于预防死亡至关重要。HLH虽然主要影响婴儿,但也可发生于儿童和成人。它分为原发性和继发性,原发性HLH是遗传性的,主要影响儿童。继发性HLH由感染、恶性肿瘤、代谢紊乱和风湿性疾病引发。诊断基于HLH-2004标准,综合考虑临床和实验室参数。早期诊断和治疗可改善预后。治疗遵循HLH-94和HLH-2004方案,包括为期八周的环孢素、皮质类固醇和依托泊苷诱导治疗。本病例描述了一名26岁女性被诊断为HLH并根据该方案成功治疗。患者病情好转并出院,证明了成人HLH病例早期诊断和适当管理的重要性。